probody
(2)
CytomX Therapeutics
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company in South San Francisco that engineers conditionally activated antibody therapeutics through its proprietary PROBODY platform. By masking a drug's binding site and unmasking it only in the tumor microenvironment - where specific proteases cut a cleavable linker - CytomX aims to hit cancer targets that are otherwise too toxic to drug, widening the therapeutic window for antibody-drug conjugates, T-cell engagers and cytokines. Its wholly owned pipeline is led by CX-2051, an EpCAM-targeting PROBODY ADC for metastatic colorectal cancer, alongside masked interferon CX-801 and T-cell engager CX-904, and it partners its technology with Amgen, Astellas, Bristol Myers Squibb, Moderna and Regeneron.
Sean McCarthy
Sean McCarthy is the chairman, president and CEO of CytomX Therapeutics, a clinical-stage biopharma in South San Francisco building 'Probody' conditionally activated antibodies that switch on inside the tumor and stay quiet everywhere else. An Oxford-trained cancer biologist turned operator, he has run CytomX since 2011, taking it from a venture-backed startup to a Nasdaq-listed company with partnerships across Bristol Myers Squibb, AbbVie, Amgen, Astellas, Moderna and Regeneron.